PBT2 from the Doherty Institute news site., page-39

Remember Pixi back in 2012 they predicted first in man trials for PBT434 by 2014, then they just let 4 years of patent protection slip away and did not get even a phase 1 in healthy patients started till the end of 2018. I can see why you would be worried on that record, This time it is maybe a bigger deal, and the institutions involved in the discovery are specialized and full on looking for a drug to treat antibiotic resistance. I doubt Prana could even stop progress for PBT2 on that front. The Doherty even reports directly to W.H.O.
Once again, referring back to PBT434, because of that 4 year delay PBT434 was not P2 trial ready, so DFP was the only option when everyone was ready to test for iron removal in PD. Unlike other chelators DFP, like PBT434 can cross the BBB. The reason I use that example is that PBT2 is not the only metal chelating antibiotic out there. For instance tetracycline is a pretty good chelator of iron, but I have no idea about zinc and ability of tetracycline to cross the BBB or bacteria outer membrane. 
Prana sure seem to have their job security in place. I am not sure how they manage the US owned shares, which I think now are the majority. I owned ADR's and was never offered an opportunity to vote. we have sure tried hard here to needle them into saying something, but for whatever reason they refuse to comment. Arrogance? Maybe. Commercial necessity? maybe. Something else, hope not. Good luck.